Sales & Marketing News | pharmaphorum

News

$refractory chronic gout$

Sobi starts rolling FDA filing for chronic gout drug

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to cu

News

Apellis will appeal CHMP’s rejection of pegcetacoplan

Apellis Pharma has said it will seek a re-evaluation of its marketing application for Syfovre for eye disease geographic atrophy (GA) after the EMA’s human medicines committee turned it dow

News

FTC launches probe of Teva over ‘improper’ patents; report

Shares in Teva Pharmaceutical have dipped sharply after reports that the Federal Trade Commission (FTC) has opened an investigation into the company focusing on improperly listed patents in

News

AstraZeneca files rival to Pemgarda for COVID PrEP

AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP).

News

First intranasal Epipen alternative backed in EU

An alternative to epinephrine autoinjectors that can be delivered by a nasal spray is close to approval in Europe after being recommended for approval by the EMA’s human medicines committee

News

Purdue’s bankruptcy plan in tatters as SCOTUS says no

The Supreme Court of the US has rejected a bankruptcy deal that would settle opioid litigation against Purdue Pharma, but also protect the Sackler family that controls the company from liab

Sobi starts rolling FDA filing for chronic gout drug

Apellis will appeal CHMP’s rejection of pegcetacoplan

FTC launches probe of Teva over ‘improper’ patents; report

AstraZeneca files rival to Pemgarda for COVID PrEP

First intranasal Epipen alternative backed in EU

Purdue’s bankruptcy plan in tatters as SCOTUS says no

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks